Nasdaq:US$17.78 (-0.53) | HKEX:HK$28.20 (-1.15) | AIM:£2.69 (-0.04)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer